InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

InflaRx N.V. (NASDAQ: IFRX) opened Friday in the red. The German-based biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced that it will ...

Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) announced today that Health Canada has granted a Notice of Compliance (NOC) for Fabhalta® (iptacopan ...

Restricting calorie intake in species such as mice, rhesus monkeys, and fruit flies has been shown to extend their lifespans. In some cases, these animals not only live longer, but are also free of ...

Regeneron rebounds from regulatory and clinical setbacks as Dupixent and pipeline catalysts fuel growth. Click here to read ...

As protectionism rises and the WTO falters, global trade is being rewired, not collapsing. New hubs centered on the European ...

Yale researchers have previously shown that people who undergo moderate calorie restriction—a 14% reduction in calorie intake ...

A new set of drugs exploit a recently-revealed weakness in 'zombie-like' – or senescent – cells that could lead to new ...

Digital transformation and artificial intelligence (AI) in health care requires a range of safeguards and standards to work ...

A study published in Ageing Research Reviews and led by MA Yinzhong's team from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences provided an integrated ...

Indian health delivery systems have been facing structural challenges for several decades. These challenges include chronic ...

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp ...